4BASEBIO PLC

Director's Dealing • Jul 13, 2022

National Storage Mechanism | Additional information

4basebio Plc - Director/PDMR Shareholding

PR Newswire

London, July 12

13 July 2022

**4basebio plc

(the "Company")**

Director’s Dealing

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, announces that it was notified on 12 July 2022 that Dr Heikki Lanckriet, chief executive officer, on the same day transferred 29,000 ordinary shares at a price of 415 pence per share from his personal holding into his SIPP (the “Transfer”).

Following the Transfer, there is no change to Dr Heikki Lanckriet’s beneficial holding, and his interest in the Company remains at 1,252,453 Ordinary Shares, representing approximately 10.17% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio plc	+44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated Adviser)	+44 (0)20 7213 0880
Jo Turner / Sandy Jamieson
finnCap Ltd (Broker)	+44 (0)20 7220 0500
Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Dr Heikki Lanckriet
2	Reason for notification
a.	Position/Status	Chief Executive Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	4basebio plc
b.	LEI	213800E2DX9EAIUNCB30
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares   ISIN: GB00BMCLYF79
b.	Nature of the transaction	Transfer from nominee account to SIPP
c.	Price(s) and volume(s)
	Price(s) per share (p)	Volume(s)
415p	29,000
d.	Aggregated information	- 29,000 - 415 pence per share
e.	Date of the transaction	12/07/2022
f.	Place of the transaction	London Stock Exchange, AIM